Efficacy and Safety of Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) in Chronic Pain Conditions Compared with Placebo in Maintaining Functional Improvement and Quality of Life: A Systematic Review

TL;DR

This paper reviews how well SNRIs like duloxetine help with chronic pain compared to placebo, focusing on pain reduction and quality of life improvements.

Contribution

The study provides a systematic review comparing SNRIs to placebo for chronic pain, highlighting duloxetine's efficacy across multiple pain types.

Findings

Duloxetine showed significant pain reduction and improved function in chronic pain conditions like osteoarthritis and fibromyalgia.

Improvements in quality of life were more pronounced with SNRIs compared to placebo.

Long-term efficacy and safety of SNRIs remain unclear and require further research.

Abstract

Aims: With this systematic review, an attempt will be made to systematically compare the efficacy and side effects of Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) in Chronic Pain Conditions in terms of functional improvement and quality of life with placebo.

Methods: The relevant studies were included after conducting a literature search in OVID, PubMed/MEDLINE, EMBASE/SIGLE, CINAHL, and Web of Science. Randomized controlled trials that compared SNRIs in chronic pain were included in the review. In the assessment of study quality, the Cochrane Risk-of-Bias tool was used. A number of data extractors and analysts were used in the study so as to reduce possible bias in the study results.

Results: Duloxetine appeared to be the SNRI with the best therapeutic efficacy profile across different chronic pain types and aetiologies such as osteoarthritis, fibromyalgia, and chronic low back pain. It showed reasonable effectiveness in alleviating pain magnitude and enhancing motor activity. The results were consistent between standard and higher doses of single administration 60 mg. Duloxetine demonstrated a significant reduction in pain when compared with placebo. An improvement in functional status and quality of life measured through self-reported scales was also noted. This trend was more pronounced in the treatment of the patients on SNRI compared with those on placebo.

Conclusion: Duloxetine appears to be effective for chronic pain conditions and may help reduce pain intensity, increase functional status and improve the quality of life. Even though rigorous trials indicate that these drugs are superior to placebo after 8–16 weeks, long-term effect and safety profiles are not very clear, and more long-term studies are needed to understand the durability and application of the drugs in clinical practices. Further research should prospectively investigate the efficacy in long-term pain, different comorbid conditions, and include predictors of SNRI response.